Snapshot from Aug 01, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / NeuroThera initiates Phase IIb Tourette trial
Business clinical trial initiation

NeuroThera initiates Phase IIb Tourette trial

Analysis based on 6 articles · First reported Jul 15, 2026 · Last updated Jul 15, 2026

Sentiment
10
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The initiation of the Phase IIb trial represents a positive step for NeuroThera and its parent SciSparc, potentially boosting investor confidence in their drug pipeline. However, as a clinical-stage event with no immediate revenue impact, market attention is expected to be modest.

Pharmaceuticals Biotechnology
Event Summary

SciSparc Ltd. announced that its subsidiary NeuroThera Labs Inc. Inc. initiated a Phase IIb clinical trial site at Hannover Medical School in Germany for SCI-110, a cannabinoid-based treatment for Tourette Syndrome in adults. The trial previously received regulatory clearance from Germany's Germany — Federal Institute for Drugs and Medical Devices and ethics committee approval. Additional sites include Yale Child Study Center and Tel Aviv Sourasky Medical Center. The randomized, double-blind, placebo-controlled crossover trial will evaluate efficacy, safety, and tolerability of daily oral SCI-110 in patients aged 18-65, with primary endpoint being change in tic severity at weeks 12 and 26.

Key Actions
80 NeuroThera Labs Inc. initiated Phase IIb trial
60 Germany — Federal Institute for Drugs and Medical Devices granted regulatory clearance NeuroThera Labs Inc.
50 Hannover Medical School approved ethics committee NeuroThera Labs Inc.
Entities Involved
priv
NeuroThera Labs Inc.
NeuroThera is the subsidiary conducting the trial. Successful Phase IIb results could lead to regulatory approval and commercialization of SCI-110.
Importance 100.0 Sentiment 20.0
stock
SciSparc
SciSparc is the parent company of NeuroThera and stands to benefit from positive trial outcomes. The announcement may improve its stock sentiment.
Importance 80.0 Sentiment 15.0
oth
Hannover Medical School
Hannover Medical School is a clinical trial site hosting the study. Its involvement lends credibility but no direct financial impact.
Importance 40.0 Sentiment 0.0
govactor
Germany — Federal Institute for Drugs and Medical Devices
The German regulatory body granted clearance for the trial, enabling the study to proceed in Germany.
Importance 30.0 Sentiment 0.0
oth
Yale Child Study Center
Yale Child Study Center is an additional trial site in the US, contributing to patient enrollment and data collection.
Importance 30.0 Sentiment 0.0
cnt
Germany
Germany is the country where the trial site is located; regulatory approval from its authorities was obtained.
Importance 20.0 Sentiment 0.0
per
Adi Zuloff-Shani
Dr. Adi Zuloff-Shani is the Chief Technology Officer of NeuroThera and commented on the trial initiation, but has no direct financial stake.
Importance 20.0 Sentiment 0.0
cnt
United States
The US hosts the Yale Child Study Center trial site and is a potential market for SCI-110.
Importance 10.0 Sentiment 0.0
cnt
Israel
Israel is the home country of SciSparc and NeuroThera, and hosts one trial site.
Importance 10.0 Sentiment 0.0
Relationships
Germany strained ally ↔ United States Germany remains a key defense partner of the United States, deepening its reliance on American military technology, but
Germany related ↔ Israel
United States close ally ↔ Israel The United States considers Israel a vital strategic ally in the Middle East, providing substantial military and economi
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.